The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
about
RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.Rictor is an independent prognostic factor for endometrial carcinoma.Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumorsVascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancerRPPA-based protein profiling reveals eIF4G overexpression and 4E-BP1 serine 65 phosphorylation as molecular events that correspond with a pro-survival phenotype in chronic lymphocytic leukemia.DNA damage-induced S and G2/M cell cycle arrest requires mTORC2-dependent regulation of Chk1.Downregulation of LRRC8A protects human ovarian and alveolar carcinoma cells against Cisplatin-induced expression of p53, MDM2, p21Waf1/Cip1, and Caspase-9/-3 activation.miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting METmTORC1 and -2 Coordinate Transcriptional and Translational Reprogramming in Resistance to DNA Damage and Replicative Stress in Breast Cancer Cells.Overexpression of Rictor protein in colorectal cancer is correlated with tumor progression and prognosis.The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis.p53 and metabolism: from mechanism to therapeutics.
P2860
Q33435610-D3354A1C-9757-43D9-AC45-A85D29C29DFCQ33802841-4266B4A3-5D4D-4040-99B5-5A27ABE25B88Q35356038-754179C2-B634-48B3-8B4D-5942B396DB76Q35992948-89039F84-43A5-4E52-B6A5-0EFCC0BF1DD4Q38872127-2FCECF01-8156-4881-B7B3-21CBB891EA34Q38933652-44C23782-E35B-41D8-A286-763F64069B5BQ39914343-00D7E156-D363-4B1C-AAC4-5B2E937FF058Q41134348-3DBF3837-3A4F-4ADA-B4F1-8B447F92107FQ42321289-014CB240-FEEE-4E22-809B-AB65200FD6A7Q47429788-49901D69-F584-48D6-82B1-6914914A3222Q52727884-8A2CC9F5-F509-48EF-8694-0148F0A8DC3CQ55002919-549AC7D2-F5F7-4392-9BB4-92AA326B4E8F
P2860
The mTORC2 component rictor contributes to cisplatin resistance in human ovarian cancer cells.
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@ast
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@en
type
label
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@ast
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@en
prefLabel
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@ast
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@en
P2093
P2860
P1433
P1476
The mTORC2 component rictor co ...... in human ovarian cancer cells.
@en
P2093
Akechai Im-aram
Gwonhwa Song
Jae Yong Han
Lee Farrand
Seung-Min Bae
Yong Sang Song
P2860
P304
P356
10.1371/JOURNAL.PONE.0075455
P407
P577
2013-09-23T00:00:00Z